To the full analysis
Genmab stock: growth
GMAB.COGenmab reported $3.86B in revenue for fiscal 2025, down 82.1% on the prior year, down 17.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
19.3%
per year from 2006 to 2025, per share 16.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −17.5% | 13.0% | 19.3% |
| Revenue per share | −16.7% | 12.4% | 16.4% |
| Earnings | −26.8% | 2.7% | no data |
| Earnings per share | −26.1% | 2.1% | no data |
| Free cash flow | −27.9% | 21.1% | no data |
| Free cash flow per share | −27.2% | 20.4% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $135.55M | −$438.24M | −$381.56M |
| 2007 | $529.54M | −$383.37M | $493.06M |
| 2008 | $692.3M | −$965.09M | −$566.35M |
| 2009 | $586.08M | −$1.01B | −$586.84M |
| 2010 | $582.08M | −$321.46M | $258.06M |
| 2011 | $350.94M | −$596.37M | −$444.43M |
| 2012 | $484.64M | −$487.12M | $61.92M |
| 2013 | $663.57M | $112.36M | −$138.36M |
| 2014 | $850.39M | $301.3M | $57.23M |
| 2015 | $1.13B | $763.51M | $176.06M |
| 2016 | $1.82B | $1.19B | $294.61M |
| 2017 | $2.37B | $1.1B | $1.5B |
| 2018 | $3.03B | $1.47B | $537.42M |
| 2019 | $5.37B | $2.17B | $1.22B |
| 2020 | $10.11B | $4.76B | $6.13B |
| 2021 | $8.48B | $2.96B | $1.98B |
| 2022 | $14.51B | $5.45B | $3.6B |
| 2023 | $16.47B | $4.35B | $7B |
| 2024 | $21.53B | $7.84B | $7.58B |
| 2025 | $3.86B | $999.19M | $1.19B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.